{"product_id":"dynavax-business-model-canvas","title":"Dynavax Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDynavax Business Model Canvas: Vaccine Strategy, Revenue \u0026amp; Templates in One Download\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock the full strategic blueprint behind Dynavax’s business model—this concise Business Model Canvas maps core activities, partners, and revenue levers that drive its vaccine-focused growth.\u003c\/p\u003e\n\u003cp\u003ePerfect for investors, advisors, and founders, the downloadable Canvas breaks down value propositions, cost structure, and market positioning for immediate analysis.\u003c\/p\u003e\n\u003cp\u003ePurchase the full Word\/Excel kit to access all nine blocks with company-specific insights and ready-to-use templates for strategic planning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Adjuvant Collaborators\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDynavax partners with global vaccine developers to incorporate its CpG 1018 adjuvant into candidates, including a 2024\/25 supply and development deal with India’s Biological E and a 2023 commercial pact with Valneva for enhanced hepatitis and COVID vaccine formulations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Distribution Partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDynavax partners with local distributors to supply HEPLISAV-B and other vaccines, outsourcing cold-chain logistics, regulatory filings, and customs to firms that cover 45+ countries; this avoided an estimated $40–60M in fixed global infrastructure spend through 2024 while supporting 22% annual international shipment growth in 2023–2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eContract Manufacturing Organizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDynavax uses third-party Contract Manufacturing Organizations (CMOs) to produce active pharmaceutical ingredients and provide fill-finish services for HEPLISAV-B; in 2024 CMOs supported annualized capacity near 10 million doses, enabling variable supply to match demand spikes. Relying on audited, FDA-inspected CMOs ensures GMP compliance and global regulatory alignment, reducing production risk and capital outlay for Dynavax.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and Academic Institutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eDynavax partners with top universities (e.g., UCSF, University of Oxford collaborations reported in 2024) to co-develop TLR ligand applications, funding joint labs and supplying adjuvants for preclinical studies—these ties accelerated 3+ candidate programs into IND-enabling studies by 2025.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAcademic collaborations cut early-stage cost, ~20% of preclinical budget saved (2023–2025)\u003c\/li\u003e\n\u003cli\u003eSupported 3 IND-enabling programs by 2025\u003c\/li\u003e\n\u003cli\u003eAccess to \u0026gt;200 immunology specialists and core labs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment and Public Health Agencies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eDynavax partners with CDC and state health departments to supply clinical and post-market data that led to ACIP (Advisory Committee on Immunization Practices) recommendation for HEPLISAV-B in 2018 and supported uptake—U.S. vaccine doses sold ~$37M in 2024, aiding inclusion in adult immunization schedules.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eData sharing drove ACIP recommendation (2018)\u003c\/li\u003e\n\u003cli\u003eState-level adoption affects reimbursement and distribution\u003c\/li\u003e\n\u003cli\u003e2024 U.S. HEPLISAV-B sales ≈ $37M, public programs key\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDynavax leverages CMOs, CpG partnerships to scale 10M doses, cut $40–60M, $37M US sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDynavax outsources manufacturing and distribution, supplies CpG 1018 to partners (Biological E 2024\/25, Valneva 2023), and funds academic R\u0026amp;D; CMOs enabled ~10M dose capacity (2024), saved ~$40–60M in infrastructure to 2024, supported 22% intl shipment growth (2023–24), and U.S. HEPLISAV-B sales ≈ $37M (2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePartnership\u003c\/th\u003e\n\u003cth\u003eKey 2024–25 Data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCMOs\u003c\/td\u003e\n\u003ctd\u003e~10M dose capacity\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDistribution\u003c\/td\u003e\n\u003ctd\u003e22% intl growth; $40–60M cost avoided\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCommercial\u003c\/td\u003e\n\u003ctd\u003eHEPLISAV-B US sales $37M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA tailored Business Model Canvas for Dynavax detailing customer segments, channels, value propositions, revenue streams, key partners, activities, resources, cost structure, and customer relationships—aligned to its vaccine development, commercialization, and licensing strategy and ideal for investor presentations and strategic planning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eHigh-level view of Dynavax’s business model as a pain-point reliever—editable canvas highlighting vaccine development, commercial partnerships, and regulatory pathways to quickly pinpoint strategic gaps and streamline go-to-market decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVaccine Research and Development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDynavax centers R\u0026amp;D on advancing its clinical pipeline for shingles, Tdap, and other infectious diseases, running multiple Phase 2\/3 trials and spending about $140M on R\u0026amp;D in FY2024 to prove safety and efficacy for FDA and EMA filings.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCommercialization of HEPLISAV-B\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDynavax concentrates on commercialization of HEPLISAV-B, deploying a specialized sales force to grow adult-segment share across health systems, retail pharmacies, and government clinics; HEPLISAV-B drove $131.7 million in 2024 U.S. revenue, making it the company’s primary revenue driver. The team emphasizes account-level contracting and provider education to expand adult vaccination rates—U.S. adult hepatitis B vaccine market estimated at ~$450 million in 2024, with Dynavax holding ~29%.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdjuvant Platform Optimization\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDynavax actively manages its CpG 1018 adjuvant platform to support internal vaccines and \u0026gt;20 partner programs, refining manufacturing scale-up and GMP yields (targeting \u0026gt;90% batch success) to cut COGS and speed time-to-clinic. The company runs cross-vaccine immunogenicity and stability studies—57 trials or assays since 2018—to demonstrate efficacy across platforms, preserving technical lead and securing multi-year licensing revenue potential.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Affairs and Compliance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eDynavax spends continuous resources navigating FDA and international approvals, filing Biologics License Applications and IND\/CTA submissions while running post-market surveillance for HEPLISAV-B; in 2024 the company reported R\u0026amp;D and regulatory expenses of $72.3M, reflecting this ongoing effort.\u003c\/p\u003e\n\u003cp\u003eMaintaining GMP compliance and timely safety reporting underpins supply stability and revenue recognition, with manufacturing audits and adverse event reporting processes tied to contract manufacturers and BLA obligations.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFiles: IND\/CTA, BLA submissions and supplements\u003c\/li\u003e\n\u003cli\u003e2024 regulatory\/R\u0026amp;D spend: $72.3M (company FY2024)\u003c\/li\u003e\n\u003cli\u003eKey product: HEPLISAV-B post-market surveillance active\u003c\/li\u003e\n\u003cli\u003eGMP audits \u0026amp; safety reporting mandatory for contract manufacturers\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Business Development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eDynavax pursues strategic business development to secure licensing, partnership, and acquisition deals that diversify its vaccine pipeline and generate milestone and royalty revenue; in 2024 the company reported collaboration revenue of $12.4M, underscoring this stream.\u003c\/p\u003e\n\u003cp\u003eThis planning directs capital between internal R\u0026amp;D—$120M cash and equivalents at Q3 2025—and external deals to maximize ROI and steady cash flow.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTargets: licensing, M\u0026amp;A, partnerships\u003c\/li\u003e\n\u003cli\u003e2024 collaboration revenue: $12.4M\u003c\/li\u003e\n\u003cli\u003eQ3 2025 cash: $120M\u003c\/li\u003e\n\u003cli\u003eGoal: steady milestone\/royalty stream\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDynavax: HEPLISAV-B leader (29%); heavy R\u0026amp;D ($140M) and CpG 1018 scale-up, $120M cash\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDynavax runs clinical R\u0026amp;D (Phase 2\/3) and spent ~$140M R\u0026amp;D FY2024 to advance vaccines; commercializes HEPLISAV-B ($131.7M US rev 2024; ~29% market share of ~$450M US adult HBV market); manages CpG 1018 adjuvant scale-up (\u0026gt;20 partner programs) and regulatory\/GMP activities (regulatory\/R\u0026amp;D $72.3M 2024); 2024 collaboration revenue $12.4M; Q3 2025 cash $120M.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend FY2024\u003c\/td\u003e\n\u003ctd\u003e$140M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory\/R\u0026amp;D 2024\u003c\/td\u003e\n\u003ctd\u003e$72.3M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHEPLISAV-B US revenue 2024\u003c\/td\u003e\n\u003ctd\u003e$131.7M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS adult HBV market 2024\u003c\/td\u003e\n\u003ctd\u003e$450M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDynavax share\u003c\/td\u003e\n\u003ctd\u003e~29%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCollaboration revenue 2024\u003c\/td\u003e\n\u003ctd\u003e$12.4M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ3 2025 cash\u003c\/td\u003e\n\u003ctd\u003e$120M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe document you're previewing is the authentic Dynavax Business Model Canvas — not a mockup or sample — and it's the exact file you'll receive after purchase; when you complete your order, you'll get full access to this same professional, ready-to-use document in editable Word and Excel formats.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56748718227833,"sku":"dynavax-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/dynavax-business-model-canvas.png?v=1772210795","url":"https:\/\/matrixbcg.com\/products\/dynavax-business-model-canvas","provider":"MatrixBCG","version":"1.0","type":"link"}